Research programme: antibody-based cancer therapeutics - Menarini/Oxford BioTherapeutics

Drug Profile

Research programme: antibody-based cancer therapeutics - Menarini/Oxford BioTherapeutics

Alternative Names: OX-002

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioTherapeutics
  • Developer Menarini; Oxford BioTherapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action DEC-205 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Oct 2014 Preclinical trials in Breast cancer in Europe (Parenteral)
  • 02 Oct 2014 Preclinical trials in Non-Hodgkin's lymphoma in Europe (Parenteral)
  • 08 May 2014 Oxford BioTherapeutics in-licenses Antibody Drug Conjugate (ADC) technology from ImmunoGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top